Printer Friendly

UCI CANCER SPECIALIST RECEIVES GIFT OF SUPPORT FOR WORK ON MULTIPLE MYELOMA; PATIENTS NEEDED FOR NEW TREATMENT STUDIES

 ORANGE, Calif., March 23 /PRNewswire/ -- UCI Clinical Cancer Center faculty member Dr. Jose Lutzky has received an $85,000 gift of support from Roche Laboratories for his work on multiple myeloma. Lutzky is an assistant professor of Medicine, division of hematology/oncology, at UCI Medical Center in Orange. Roche Laboratories is a division of Hoffmann-La Roche Inc.
 In 1992, Lutzky founded the Clinical Cancer Center's Multidisciplinary Lymphoma Program, which he directs. The program focuses on non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma. Lymphomas and Hodgkin's disease are cancers that involve the lymph nodes, and also may attack bone marrow. Multiple myeloma affects the plasma cells which the immune system develops to fight infections and disease.
 Lutzky is presently investigating new treatment methods for patients with advanced stages of multiple myeloma and non-Hodgkin's lymphoma, and is currently recruiting patients with these forms of cancer for clinical studies.
 A recently activated study at UCI for advanced multiple myeloma is investigating a combination of natural products. One is a derivative of vitamin A, known as all-transretinoic acid. The other product is alpha-interferon, which is produced by human cells to defend healthy cells against viral infections. Early laboratory studies suggest that the combination of these two products could be highly effective for the treatment of myeloma.
 According to the American Cancer Society's California study of selected cancer sites (1974-1985), the five-year cancer survival rate for all stages of non-Hodgkin's lymphoma is approximately 50 percent. Although not yet proven, it has been suggested that viruses may cause certain types of non-Hodgkin's lymphoma as well as Hodgkin's disease. Multiple myeloma cases studied between 1981 and 1986 indicate a five- year survival rate of approximately 26 percent (as determined by the Cancer Statistics Branch of the National Cancer Institute).
 After receiving a medical degree from Federal University, Brazil, Lutzky served his residency at Mount Sinai Medical Center and Jackson Memorial Hospital, both University of Miami Hospitals in Florida. He completed a hematology/oncology fellowship at Columbia-Presbyterian Medical Center, Columbia University, New York, where he subsequently joined the faculty. In 1989, Lutzky relocated to Long Beach Veterans Administration Hospital as a faculty member of the University of California, Irvine. Lutzky relocated his activities to UCI Medical Center in 1991.
 Cancer patients with a confirmed diagnosis of multiple myeloma or non-Hodgkin's lymphoma may be eligible to participate in new treatment studies at UCI. Those interested should contact Nancy Downey-Hurtado, R.N., at the UCI Multidisciplinary Lymphoma Program at 714-456-5152.
 -0- 3/23/93
 /CONTACT: Leslie Ann Cyril of UCI Clinical Cancer Center, 714-456-5989/


CO: UCI Clinical Cancer Center; Roche Laboratories ST: California IN: MTC SU:

MS-JL -- LA003 -- 8590 03/23/93 10:31 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 23, 1993
Words:445
Previous Article:CST ENTERTAINMENT IMAGING INC. ANNOUNCES SALE OF SHARES OF COMMON STOCK
Next Article:BRAUNS FASHIONS CORPORATION IMPLEMENTS NEW MIS SYSTEM
Topics:


Related Articles
Celgene Announces Plans to Pursue Multiple Myeloma Indication for THALOMID(TM) (THALIDOMIDE).
Clinical Trial Results on the Use of Celgene's Thalomid(R) (Thalidomide) in Treating Both Early Stage and Refractory Multiple Myeloma Presented.
IMiDs(TM) Activity Against Multiple Myeloma Cells Presented At the American Society of Hematology Meeting.
New Clinical Research Trial Results Suggest THALOMID(R) and IMIDS Affect Myeloma at Every Stage of the Disease; - Sixty-nine Abstracts on THALOMID...
The Multiple Myeloma Research Foundation (MMRF) Announces 2003 Collaborative Program Grant Recipient; $1.5 million awarded to accelerate cutting-edge...
Survey of Oncologists Reveals Significant Opportunity to Get More Multiple Myeloma Patients Into Clinical Trials; Multiple Myeloma Research...
Clinical Data on ACTIMID(TM) in Multiple Myeloma at The American Society of Hematology 45th Annual Meeting; 93% of Evaluable Patients Achieved...
Clinical Data on REVIMID(TM) in Relapsed or Refractory Multiple Myeloma Presented at the American Society of Hematology 45th Annual Meeting; * 91...
CuraGen and TopoTarget Initiate Phase II Trial of Belinostat (PXD101) in Combination with Velcade(R) for Refractory Multiple Myeloma.
The Multiple Myeloma Research Consortium and Nereus Pharmaceuticals Initiate Clinical Trial Investigating NPI-0052 to Treat Multiple Myeloma.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters